7.82
price down icon1.51%   -0.12
after-market Handel nachbörslich: 7.82
loading
Schlusskurs vom Vortag:
$7.94
Offen:
$8.03
24-Stunden-Volumen:
3.30M
Relative Volume:
1.82
Marktkapitalisierung:
$2.45B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-11.49
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
+0.90%
1M Leistung:
+5.39%
6M Leistung:
+0.51%
1J Leistung:
+15.85%
1-Tages-Spanne:
Value
$7.76
$8.03
1-Wochen-Bereich:
Value
$7.75
$8.11
52-Wochen-Spanne:
Value
$6.29
$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name
Firmenname
Amneal Pharmaceuticals Inc
Name
Telefon
908-947-3120
Name
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Name
Mitarbeiter
5,210
Name
Twitter
@amnealpharma
Name
Nächster Verdiensttermin
2025-05-02
Name
Neueste SEC-Einreichungen
Name
AMRX's Discussions on Twitter

Vergleichen Sie AMRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
AMRX
Amneal Pharmaceuticals Inc
7.82 2.45B 2.68B -184.45M 229.23M -0.6805
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
38.01 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
157.17 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.41 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.77 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.95 20.17B 16.54B -1.64B 749.00M -1.45

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-06 Eingeleitet Goldman Buy
2025-02-24 Hochstufung JP Morgan Neutral → Overweight
2024-09-06 Hochstufung JP Morgan Underweight → Neutral
2021-04-07 Fortgesetzt RBC Capital Mkts Sector Perform
2021-03-08 Hochstufung Goldman Sell → Buy
2020-12-14 Hochstufung Barclays Equal Weight → Overweight
2020-12-14 Hochstufung Guggenheim Neutral → Buy
2020-07-27 Eingeleitet Goldman Sell
2020-05-12 Hochstufung Guggenheim Sell → Neutral
2019-12-12 Herabstufung Raymond James Outperform → Mkt Perform
2019-11-12 Herabstufung JP Morgan Neutral → Underweight
2019-11-07 Herabstufung SVB Leerink Outperform → Mkt Perform
2019-07-22 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-07-11 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2019-07-08 Hochstufung Piper Jaffray Neutral → Overweight
2019-06-11 Eingeleitet Barclays Equal Weight
2019-05-21 Hochstufung Raymond James Mkt Perform → Strong Buy
2019-03-20 Eingeleitet SunTrust Buy
2019-03-08 Herabstufung SVB Leerink Outperform → Mkt Perform
2018-12-14 Herabstufung Morgan Stanley Overweight → Equal-Weight
2018-10-16 Herabstufung SunTrust Buy → Hold
2018-08-13 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2018-07-23 Eingeleitet Morgan Stanley Overweight
2018-06-22 Eingeleitet B. Riley FBR, Inc. Buy
Alle ansehen

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

pulisher
Jun 18, 2025

Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmac - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Parkinson’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma - Barchart.com

Jun 17, 2025
pulisher
Jun 17, 2025

Parkinson's Disease Market to Show Remarkable Growth Trends - openPR.com

Jun 17, 2025
pulisher
Jun 13, 2025

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - Yahoo Finance

Jun 13, 2025
pulisher
Jun 13, 2025

Epinephrine Autoinjector Market Size, Share, and Competitive - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves Amneal’s prednisolone acetate eye drops, launch set for Q3 - Investing.com India

Jun 13, 2025
pulisher
Jun 12, 2025

Insider Sell: Gautam Patel Sells 56,426 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Pharmaceuticals (AMRX) Gains FDA Approval for Eye Drug | AMRX Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

FDA Green Lights Amneal's $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative - Stock Titan

Jun 12, 2025
pulisher
Jun 11, 2025

Amneal Recalls Oral Antibiotic Over Contamination Issue - Infectious Disease Advisor

Jun 11, 2025
pulisher
Jun 10, 2025

Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision By Investing.com - Investing.com Canada

Jun 10, 2025
pulisher
Jun 10, 2025

Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision - Investing.com

Jun 10, 2025
pulisher
Jun 09, 2025

Selective Estrogen Receptor Modulators Market Research 2025-2030: Leading Players Shaping the Future of Selective Estrogen Receptor Modulators Industry - GlobeNewswire Inc.

Jun 09, 2025
pulisher
Jun 09, 2025

Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) PT at $11.60 - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Wellington Management Group LLP Has $586,000 Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Amneal Pharmaceuticals (NASDAQ:AMRX) Coverage Initiated by Analysts at The Goldman Sachs Group - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.52 Million Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

Teva stock, Amneal stock, rated Buy at Goldman (TEVA:NYSE) - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

Amneal recalls oral antibiotic due to bacterial contamination - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

AMRX Stock Coverage Initiated with Buy Rating by Goldman Sachs | AMRX Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating By Investing.com - Investing.com UK

Jun 06, 2025
pulisher
Jun 06, 2025

Two Sigma Advisers LP Sells 32,400 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Amneal Pharmaceuticals at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Amneal Pharmaceuticals Initiates Nationwide Recall of Contaminated Sulfamethoxazole/Trimethoprim Tablets - Insider Monkey

Jun 05, 2025
pulisher
Jun 04, 2025

Amneal Pharmaceuticals (AMRX) Recalls Antibiotic Due to Contamination - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal announces recall of oral antibiotic (AMRX:NASDAQ) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal Pharmaceuticals (AMRX) Recalls Contaminated Tablets Due t - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal Recalls Three Lots of Urinary Tract Infection Tablets - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade - sharewise

Jun 04, 2025
pulisher
Jun 01, 2025

Amneal Pharmaceutical LLC Issues a Nationwide Recall of Sulfamethoxazole / Trimethoprim Tablets, USP, 400 mg/80 mg Only, Due to Microbial Contamination - US Recall News

Jun 01, 2025
pulisher
May 29, 2025

Amneal to Participate at Upcoming Investor Conferences in June - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Amneal CEO and CFO Set for Exclusive Presentations at Two Major Healthcare Investor Conferences - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Bank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 29, 2025
pulisher
May 28, 2025

FDA approves Amneal’s DHE migraine/cluster headache autoinjector - MSN

May 28, 2025
pulisher
May 28, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $716,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 28, 2025
pulisher
May 27, 2025

Pharyngitis Treatment Market with Antibiotics and Home - openPR.com

May 27, 2025
pulisher
May 26, 2025

3 Reasons Growth Investors Will Love Amneal (AMRX) - Yahoo Finance

May 26, 2025
pulisher
May 26, 2025

Deutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 26, 2025
pulisher
May 22, 2025

Hydroxychloroquine Market to Witness Remarkable Growth with - openPR.com

May 22, 2025
pulisher
May 22, 2025

Insider Sell: Nikita Shah Sells Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight - PR Newswire

May 21, 2025
pulisher
May 20, 2025

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial Markets - Defense World

May 20, 2025

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Amneal Pharmaceuticals Inc-Aktie (AMRX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Shah Nikita
Executive Vice President
May 16 '25
Sale
7.58
49,140
372,481
388,929
$13.46
price up icon 0.98%
$8.87
price up icon 1.14%
$126.55
price down icon 0.60%
$290.75
price down icon 0.33%
drug_manufacturers_specialty_generic RDY
$15.23
price up icon 0.26%
$16.95
price down icon 0.64%
Kapitalisierung:     |  Volumen (24h):